161 related articles for article (PubMed ID: 1287140)
21. Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests.
Cartledge JD; Midgley J; Petrou M; Shanson D; Gazzard BG
J Antimicrob Chemother; 1997 Oct; 40(4):517-23. PubMed ID: 9372421
[TBL] [Abstract][Full Text] [Related]
22. Resistant candidiasis.
Powderly WG
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):925-9. PubMed ID: 7811544
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility and sterol biosynthesis of Candida albicans strains after long-term treatment with azoles in HIV-infected patients.
Hundt W; Hofmann H
Infection; 1994; 22(2):124-31. PubMed ID: 8070926
[TBL] [Abstract][Full Text] [Related]
24. Treatment of refractory oral candidiasis with fluconazole. A case report.
Lucatorto FM; Franker C; Hardy WD; Chafey S
Oral Surg Oral Med Oral Pathol; 1991 Jan; 71(1):42-4. PubMed ID: 1994321
[TBL] [Abstract][Full Text] [Related]
25. Fluconazole-resistant oral candidosis in a repeatedly treated female AIDS patient.
Thomas-Greber E; Korting HC; Bogner J; Goebel FD
Mycoses; 1994; 37(1-2):35-8. PubMed ID: 7935590
[TBL] [Abstract][Full Text] [Related]
26. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis.
Force RW; Nahata MC
Ann Pharmacother; 1995 Jan; 29(1):10-5. PubMed ID: 7711339
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.
Vazquez JA; Skiest DJ; Tissot-Dupont H; Lennox JL; Boparai N; Isaacs R
HIV Clin Trials; 2007; 8(2):86-97. PubMed ID: 17507324
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients.
Vazquez JA
HIV Clin Trials; 2000; 1(1):47-59. PubMed ID: 11590489
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of melaleuca oral solution for the treatment of fluconazole refractory oral candidiasis in AIDS patients.
Jandourek A; Vaishampayan JK; Vazquez JA
AIDS; 1998 Jun; 12(9):1033-7. PubMed ID: 9662200
[TBL] [Abstract][Full Text] [Related]
30. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Walsh TJ; Gonzalez CE; Piscitelli S; Bacher JD; Peter J; Torres R; Shetti D; Katsov V; Kligys K; Lyman CA
J Clin Microbiol; 2000 Jun; 38(6):2369-73. PubMed ID: 10835005
[TBL] [Abstract][Full Text] [Related]
31. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole.
Meunier F; Aoun M; Gerard M
Rev Infect Dis; 1990; 12 Suppl 3():S364-8. PubMed ID: 2184513
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients.
Patton LL; Bonito AJ; Shugars DA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):170-9. PubMed ID: 11505264
[TBL] [Abstract][Full Text] [Related]
33. Candidiasis at ICAAC.
Barr D; Smart T
GMHC Treat Issues; 1995 Oct; 9(10):13. PubMed ID: 11362914
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of fluconazole suspension for the treatment of oesophageal candidiasis in patients with AIDS.
Laine L; Rabeneck L
Aliment Pharmacol Ther; 1995 Oct; 9(5):553-6. PubMed ID: 8580277
[TBL] [Abstract][Full Text] [Related]
35. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial.
Laine L; Dretler RH; Conteas CN; Tuazon C; Koster FM; Sattler F; Squires K; Islam MZ
Ann Intern Med; 1992 Oct; 117(8):655-60. PubMed ID: 1308663
[TBL] [Abstract][Full Text] [Related]
36. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans.
Laguna F; Rodríguez-Tudela JL; Martínez-Súarez JV; Polo R; Valencia E; Díaz-Guerra TM; Dronda F; Pulido F
Clin Infect Dis; 1997 Feb; 24(2):124-30. PubMed ID: 9114134
[TBL] [Abstract][Full Text] [Related]
37. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression.
Walmsley S; King S; McGeer A; Ye Y; Richardson S
Clin Infect Dis; 2001 Jun; 32(11):1554-61. PubMed ID: 11340526
[TBL] [Abstract][Full Text] [Related]
38. Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study.
Parente F; Ardizzone S; Cernuschi M; Antinori S; Esposito R; Moroni M; Lazzarin A; Bianchi Porro G
Am J Gastroenterol; 1994 Mar; 89(3):416-20. PubMed ID: 8122656
[TBL] [Abstract][Full Text] [Related]
39. Itraconazole and fluconazole in oropharyngeal candidiasis.
van der Bijl P; Arendorf TM
Ann Dent; 1993; 52(2):12-6. PubMed ID: 8267372
[TBL] [Abstract][Full Text] [Related]
40. Candida albicans resistance in AIDS.
Kitchen VS; Savage M; Harris JR
J Infect; 1991 Mar; 22(2):204-5. PubMed ID: 2026898
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
